Spectrum reports record EPS after boosting Fusilev sales
This article was originally published in Scrip
Spectrum Pharmaceuticals had $46.5 million in first quarter 2012 net income and record-breaking earnings per share of $0.71 – both three times the $12.8 million in net income and $0.23 in earnings per share reported for first quarter 2011 – based on $51 million in sales of its metastatic colorectal cancer drug Fusilev (levolecovorin) and operational efficiency.
You may also be interested in...
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.